Immunome/IMNM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Immunome

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Ticker

IMNM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Clay Siegall

Employees

55

Headquarters

Bothell, United States

Immunome Metrics

BasicAdvanced
$896M
Market cap
-
P/E ratio
-$5.49
EPS
1.85
Beta
-
Dividend rate
$896M
1.85296
$30.96
$4.50
764K
10.184
-126.15%
-154.98%
-148.61%
70.641
3.123
3.137
436.51%
-121.03%

What the Analysts think about Immunome

Analyst Ratings

Majority rating from 6 analysts.
Buy

Immunome Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12,940.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-73.68%
Net income
-$129M
39.74%
Profit margin
-12,940.00%
431.02%

Immunome Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 261.78%
QuarterlyAnnual
Q1 23
Q2 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.46
-$4.22
-$2.51
-
Expected
$0.59
-$0.16
-$0.28
-$0.69
-$0.39
Surprise
-159.83%
187.50%
1,389.41%
261.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunome stock?

Immunome (IMNM) has a market cap of $896M as of June 20, 2024.

What is the P/E ratio for Immunome stock?

The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of June 20, 2024.

Does Immunome stock pay dividends?

No, Immunome (IMNM) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Immunome dividend payment date?

Immunome (IMNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunome?

Immunome (IMNM) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Immunome stock price target?

The target price for Immunome (IMNM) stock is $33.25, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Immunome stock

Buy or sell Immunome stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing